Japanese drug maker ASKA to acquire 24.9 per cent of Ha Tay Pharmaceutical JSC
Japanese drug maker ASKA to acquire 24.9 per cent of Ha Tay Pharmaceutical JSC
ASKA Pharmaceutical Co., Ltd. (ASKA) announced that the company has completed negotiations to acquire 24.9 per cent of the shares of Vietnamese pharmaceutical company Ha Tay Pharmaceutical JSC (Hataphar).
ASKA from Japan will acquire a quarter of Hataphar
|
Based on the Board Resolution to acquire the shares, ASKA signed a share assignment with Hataphar today.
Since ASKA was founded in 1920, the company has been expanding its domestic business as a specialty pharmaceutical company in the fields of internal medicine, obstetrics and gynecology, and urology. Additionally, the International Business Division was established in April 2020 with the aim to provide for the sustainable growth and development of the company through overseas business and has recently started full-scale activities.
In order to establish a business location in Southeast Asia, which has seen steady economic growth, and use it as a foothold for international business expansion, ASKA acquires a 24.9 per cent stake of Hataphar, which in 2019 was ranked as the second-largest pharmaceutical company in Vietnam by sales.
ASKA strongly believes that the collaboration through this transaction will create synergies between Hataphar's commercial structure and its own pharmaceutical development and manufacturing technology capabilities. This will considerably advance the business development of both companies and contribute significantly to improving value for our shareholders.
Going forward, ASKA will further deepen its strategic partnership with Hataphar and accelerate its business development in the Southeast Asia region.
